# Sorrento Therapeutics

Source: https://onco.cc/companies/sorrento-therapeutics/  
OnCo record `sorrento-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sorrento was a San Diego biotech with a sprawling pipeline of antibodies, cell therapies and a resiniferatoxin pain programme for cancer pain; it filed for bankruptcy in 2023.

## Summary

Sorrento Therapeutics, founded in 2006 in San Diego, built a broad portfolio spanning antibody libraries, CAR-T and dimeric antigen receptor cell therapies, a Cynviloq paclitaxel formulation and resiniferatoxin for intractable cancer pain, several of which reached phase 3. The company filed for Chapter 11 bankruptcy in 2023 and its assets were sold. Its trials remain on ClinicalTrials.gov under Sorrento as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Sorrento Therapeutics, Inc.; Sorrento
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: http://sorrentotherapeutics.com

## Sources

- Official website: http://sorrentotherapeutics.com
- ClinicalTrials.gov: trials led by Sorrento Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Sorrento%20Therapeutics%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30288730

## Connected records

- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/sorrento-therapeutics.json